瑞銀:降信義光能(0968.HK)評級至“中性” 目標價上調至5.4港元
瑞銀髮表報告指,信義光能(00968.HK)股價年初至今已上升78.5%,明顯跑贏H股及A股太陽能板塊同期的分別上升4%及30.2%。該行認為,集團表現跑贏主要由於供需緊張,使太陽能玻璃今年至今的價格上升。
該行表示,信義光能現時估值相當於今年市盈率15.2倍,對比其歷史平均的11.4倍已屬史上高位,而且集團估值與H股行業平均的14.6倍相比亦屬合理。
瑞銀相信,信義光能現時估值已反映太陽能玻璃價格上升使其毛利改善,因此該行將集團股份評級由“買入”降至“中性”,同時調整集團2019-21年每股盈利預測-5%、-7%及+4%,目標價由5港元上調至5.4港元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.